New York, September 05, 2024 - PRISM MarketView - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company utilizing biomarkers and AI algorithms to improve the diagnosis of chronic low back pain, announced a new partnership aimed at applying its Nociscan technology to the personal injury and workers compensation market in New Jersey. Led by orthopedic surgeon Dr. Justin Kubeck of Ocean Pain and Spine in Toms River, NJ, this initiative will establish a statewide network of providers using Nociscan to better evaluate low back pain cases within these legal systems.
Key Highlights:
- Strategic Partnership: Dr. Justin Kubeck will spearhead efforts to create a network of New Jersey providers using Nociscan to provide objective diagnostics for patients with chronic low back pain in the personal injury and workers compensation sectors.
- Significant Financial Impact: Personal injury claims involving the neck and back in New Jersey have an average settlement of $918,967, while work-related accidents leading to similar injuries have an average settlement of $148,750. Accurate diagnostics play a critical role in these cases.
- Objective Evaluation Tool: Nociscan’s ability to measure biomarkers in lumbar discs provides an objective diagnostic tool that can improve the evaluation process and help providers formulate and defend treatment plans in legal settings.
- Expansion Potential: Following its success in New Jersey, Aclarion plans to expand the program to other markets across the U.S., replicating this targeted approach in the personal injury and workers compensation sectors.
“This partnership is an important step toward expanding the use of Nociscan’s advanced biomarker technology in the personal injury and workers compensation market. We believe the objective data provided by Nociscan can have a significant impact on both patient care and legal outcomes.”
Ryan Bond, Chief Strategy Officer of Aclarion
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities